Nursing Contact Hours
This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center's COA.
Criteria for successful completion of this continuing nursing education program
Participants who wish to receive the full contact hour credit (3) at the conclusion of this program must:
Financial Disclosures and Conflicts of Interest
- Sign in at the nurse registration table.
- Attend the entire program.
- Complete and submit the evaluation form.
It is the policy of the Pancreatic Cancer Action Network that all continuing nursing education activities are independent, free of commercial bias and outside the control of persons or organizations with an economic interest in influencing the content. Therefore, all Pancreatic Cancer Action Network Seminar staff members, planning committee members and speakers are required to disclose any significant financial interest or relationship with the manufacturers of any commercial products discussed in an educational presentation. Any conflicts of interest are resolved prior to Seminar participation.
The following presenters disclosed the following pertinent financial relationships and how they were resolved: Within the past 12 months, Philip Philip, MD, PhD, FRCP, received a consulting fee or honorarium from Bristol-Meyers Squibb, Bayer/Onyx, Sanofi-Aventis, Curis, Lilly, Amgen, Clovis, Boehringer Ingelheim, Genomic Health, Roche, Gilead, Onyx, and Novartis. He received payment for speaking from Genentech, Bristol-Meyers Squibb, Novartis, Genvec, Chugai, Nektar, Amgen, Lilly, Roche, Bayer, Incyte and Sanofi and received research funding from Genentech, Bristol-Meyers Squibb, Novartis, Genvec, Chugai, Nektar, Amgen, Lilly, Roche, Bayer, Incyte and Sanofi. He also received fees for participation in advisory or review activities from Gilead, Onyx, Amgen, Novartis and Genentech and provision of writing assistance, medicine, equipment or administrative support from Bristol-Myers Squibb. Andrew Rhim, MD has research grants from Roche, LTD and Momenta Therapuetics. He also received a consulting fee or honorarium from Halozyme Therapeutics. All content presented by Dr. Philip and Dr. Rhim was reviewed for preference for specific commercial products by the Pancreatic Cancer Action Network.
No commercial support was provided for this program. No non-commercial support was provided for this program.
The opinions expressed in this program are those of participating speakers. Approval of this program does not imply endorsement by the Pancreatic Cancer Action Network, the approver (ONS) or ANCC of any commercial products discussed.
Some of the information contained in this program may be inconsistent with product labeling. Therefore, the official package inserts for all products mentioned should be consulted for complete prescribing information and a complete listing of indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration guidelines. Healthcare providers should exercise their own judgment in making treatment decisions.